Clinical trial
Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast…
NCT00431067 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00431067 |
|---|---|
| Title | Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy |
| Official title | Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | BIBW 2992 |
| Enrollment | 41 |
| Start date | Sep 1, 2006 |
| Primary completion | Aug 1, 2009 |
| First posted | Feb 5, 2007 |
| Last update posted | Jun 9, 2014 |
| Countries | United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: